Table 2.

Study outcomes

Outcome	Short Regimen, n=52	Standard Regimen, n=59	Risk or Mean Difference (95% Confidence Interval)	P Value
Primary outcomea
Proportion of frequent relapses or steroid dependence, n (%)	12/52 (23)	14/59 (24)	−1% (−15% to 16%)	0.90
Secondary outcomesb
Time to relapse, d	78 (0–179)	104 (54–198)	−26 (−65 to 13)	0.20
Relapse rate, per yr	1 (0–4)	1 (1–3)	−0.3 (−1 to 1.5)	0.70
Cumulative prednisolone dose, mg/m2	1193 (344–2066)	1789 (1204–2548)	−541 (−917 to −164)	0.005
Infection-associated relapses	0 (0–1)	0 (0–1)	0.1 (−0.1 to 0.4)	0.35
Other outcomesc
Relapse incidence density per 1000 patient-d	2.8 (2.7–9.7)	2.8 (2.7–8.3)	−0.4 (−2.1 to 2.8)	0.77
Duration of treatment, d	29 (8–46)	45 (35–64)	−19 (−26 to −14)	<0.001
Time to occurrence of frequent relapses or steroid dependence	206 (117–345)	156 (146–211)	−50 (−67 to 17)	0.83

The outcomes are depicted for complete case analyses of the patients with complete follow-up.

^aAssessed during 1-year follow-up.

^bOutcomes are expressed as median (interquartile range) due to non-normal distribution. Outcomes were assessed at each follow-up visit (1, 3, 6, 9, and 12 months).

^cOutcomes are expressed as median (interquartile range) due to non-normal distribution.